Avillion Has Faith In Merck's Ablynx-Rejected Psoriasis Drug

 
• By Lucie Ellis-Taitt

Avillion – which seeks co-development deals for products that otherwise could languish in busy big pharma pipelines – is taking on development of Merck's early-stage psoriasis drug, M1095, despite originator Ablynx having opted out of a co-development arrangement with the German firm for the drug four years earlier.

SC1703_Chalkboard Strategy_1200x675
Is Merck's Deal With Avillion A Strategic Portfolio Decision Or Is The Company Distancing Itself From Potential Failure? • Source: Shutterstock

More from Deals

More from Business